Background: Childhood mortality has decreased markedly over the last three decades. A study was undertaken to determine trends in deaths from respiratory illness in children in England and Wales.
Methods: Mortality data collected by the Office for National Statistics were analysed. The data included all deaths registered from all causes in children aged between 28 days and 16 years in England and Wales from 1 January 1968 to 31 December 2000. The main outcome measures were overall and age-specific mortality rates due to all respiratory disorders and specific rates for pneumonia, asthma, cystic fibrosis (CF), and bronchiolitis.
Results: In children aged 1-16 years the overall mortality rate (per 100,000 children) declined from 49.9 in 1968 to 16.3 in 2000, and rates due to respiratory illness fell from 8.6 to 1.3. The proportion of all deaths caused by respiratory illness in children aged 28 days to 16 years fell from 30.8% in 1968 to 9.9% in 2000. In post-neonatal infants (aged 28-364 days), the "all cause" mortality rate fell from 592.8 in 1968 to 176 in 2000 and the rates due to respiratory illness fell from 280 to 22.8. In 2000, pneumonia, asthma and CF together accounted for 73% of all respiratory deaths in 1-16 year olds. In this age group, mortality rates per 100,000 for pneumonia fell from 4.22 to 0.57, for asthma from 0.83 to 0.25, and for CF from 0.66 to 0.12 between 1968 and 2000. Over the same period mortality rates for pneumonia in post-neonatal infants fell from 165 to 6.78 per 100,000 and for CF from 4.88 to 0.33. Bronchiolitis mortality rates per 100,000 in post-neonatal infants fell from 21.47 in 1979 to 1.82 in 2000.
Conclusions: Mortality rates due to all respiratory illnesses in children have fallen markedly in the last three decades. This decline has been more rapid than the overall decline in childhood mortality and respiratory diseases are now responsible for a smaller proportion of deaths in children. These data could provide a foundation for assessing the impact on mortality of future health initiatives such as the introduction of a universal pneumococcal vaccination programme in England and Wales.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1747255 | PMC |
http://dx.doi.org/10.1136/thx.2005.044750 | DOI Listing |
Front Cell Infect Microbiol
January 2025
Department of Respiratory Medicine, Children' s Hospital Affiliated to Capital Institute of Pediatrics, Beijing, China.
Background: The pathogenic distribution of co-infections and immunological status of patients infected with human adenovirus serotypes 3 or 7 (HAdV-3 or HAdV-7) were poorly understood.
Methods: This study involved a retrospective analysis of respiratory specimens collected from enrolled children with lower respiratory tract infections (LRTIs), positive for HAdV-3 or HAdV-7 from January 2017 to December 2019. Demographic data, clinical features, laboratory and radiographic findings were compared to delineate the impact of co-infections, and immune responses on clinical severity of HAdV-3 or HAdV-7 infections.
SAGE Open Med
January 2025
College of Medicine King Khalid University, Abha, Saudi Arabia.
Background: The coronavirus disease 2019 (COVID-19) pandemic has affected millions of people worldwide, and although it is primarily a respiratory illness, gastrointestinal symptoms have been reported in a significant proportion of patients.
Aim: Prevalence of gastrointestinal symptoms after recovery from COVID-19.
Methodology: A community-based cross-sectional study was conducted in the Aseer region of Saudi Arabia.
Cureus
December 2024
Department of Health Sciences, Savitribai Phule Pune University, Pune, IND.
Background: Coronavirus disease 2019 (COVID-19), resulting from the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), affects various bodily systems, including the heart, central nervous system, muscles, and bones, all of which harbor angiotensin-converting enzyme 2 (ACE-2) receptors similar to those in the respiratory system. However, research on the inflammatory response and its impact on systems such as the musculoskeletal one is relatively scarce. Our study aimed to investigate bone and muscle metrics as well as handgrip strength in individuals who recuperated from COVID-19 infection.
View Article and Find Full Text PDFJ Cardiothorac Surg
January 2025
Clinical Laboratory, Anhui Hospital, Children's Hospital of Fudan University, No. 39, Wangjiang East Road, Hefei, Anhui, 230011, China.
Background: Severe pneumonia is a common disease in children, with rapid progression and easy complications of respiratory failure, endangering the lives of children. This study aimed to elucidate the clinical significance of miR-193a-5p in severe pneumonia and to provide a new biomarker for the disease.
Methods: A total of 150 children with severe pneumonia and an equal number of healthy children were selected for analysis.
Mol Med
January 2025
Center for Emerging and Re-emerging Infectious Diseases (CERID), University of Washington, Seattle, USA.
Background: Long COVID or Post-acute sequelae of COVID-19 is an emerging syndrome, recognized in COVID-19 patients who suffer from mild to severe illness and do not recover completely. Most studies define Long COVID, through symptoms like fatigue, brain fog, joint pain, and headache prevailing four or more weeks post-initial infection. Global variations in Long COVID presentation and symptoms make it challenging to standardize features of Long COVID.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!